SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

DCOY

Decoy Therapeutics, Inc
NEUTRAL
Impact 3/10
Horizonmonths Processed13d 16h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor for IND/CTA filing in 2H 2027 and any non-dilutive funding awards. Cash runway is limited; additional financing likely needed before clinical milestones.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+5
Entry
$1.11
T+0 close · Nov 3, 2026 · via day close
Latest settled
0.00%
T+5 · $1.11 · next T+20 in 15d
Vs SPY
+0.59%
α at T+5
Latest observation
−9.44%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $1.11entry
  2. T+1 · 13d ago +2.70%α +1.05% · $1.14
  3. T+5 · 7d ago 0.00%α +0.59% · $1.11
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Decoy Therapeutics reported Q3 2026 cash of $8.1M and provided a pipeline update. The lead pan-coronavirus program is expected to file a CTA/IND in 2H 2027, with once-weekly dosing potential shown in preclinical studies. No revenue or EPS was reported; the company remains pre-revenue with a cash runway that may fund operations into 2027.

Key Facts

  • Cash on balance sheet was $8.1 million at September 30, 2026, including ~$2.5M restricted Gates Foundation grant funding.
  • Lead pan-coronavirus program expected to file CTA/IND in 2H 2027.
  • Optimized lead candidate showed potential for once-weekly dosing in preclinical studies.
  • Pan-filovirus program targeting Ebola, Marburg and related viruses is being explored.
  • Company is pursuing non-dilutive funding from U.S. government and military agencies.
  • 2,385,282 shares of common stock outstanding as of September 30, 2026.
  • No revenue or EPS reported; company is pre-revenue.

Financial Impact

Cash burn rate not disclosed; $8.1M cash on hand with no revenue. Market cap ~$3M.

cashcash runway

Risk Factors

  • Cash balance of $8.1M may not be sufficient to fund operations through IND filing without additional financing.
  • Preclinical stage; no approved products or revenue.
  • Reliance on non-dilutive funding and strategic collaborations that may not materialize.
  • Forward-looking statements subject to significant regulatory and development risks.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3394089

Track record

13 reports on DCOY

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +67.67% at T+60 after the Jun 29, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Bearish 6/10 Entry $1.02 Now $0.9010 +11.66% settles Dec 15
  2. Nov 3, 202613d ago Press Release Neutral 3/10 Viewing Entry $1.11 Now $0.9010 −18.83% settles Dec 2
  3. Oct 19, 202629d ago EFFECT Neutral 4/10 Entry $1.17 to $0.9752 Now $0.9010 −22.99% ▼ −16.65% −13.19% vs SPY
  4. Oct 7, 20265w ago S-1 Bearish 6/10 Entry $1.52 to $1.14 Now $0.9010 +40.72% ▲ +25.00% +19.71% vs SPY
  5. Sep 23, 20267w ago 8-K Bearish 6/10 Entry $3.11 to $1.03 Now $0.9010 +71.03% ▲ +66.88% +66.46% vs SPY
  6. Aug 4, 202614w ago DEFA14A Neutral 3/10 Entry $4.19 to $2.98 Now $0.9010 −78.50% ▼ −28.88% −28.28% vs SPY
  7. Jul 20, 202617w ago EFFECT Neutral 4/10 Entry $5.31 to $3.52 Now $0.9010 −83.02% ▼ −33.65% −37.77% vs SPY
  8. Jun 29, 202620w ago 8-K Bearish 7/10 Entry $9.59 to $5.04 Now $0.9010 +90.60% ▲ +47.45% +47.17% vs SPY
  9. Jun 25, 202620w ago EFFECT Neutral 5/10 Entry $5.92 to $4.94 Now $0.9010 −84.78% ▼ −16.53% −17.05% vs SPY
  10. Jun 4, 202623w ago DEFA14A Neutral 3/10 Entry $6.71 to $7.31 Now $0.9010 −86.57% ▲ +8.94% +10.31% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026